Monthly Archives: August 2017

Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead

By | Uncategorized | No Comments

Molecular Partners announced its results and highlights for H1 2017, a semester in which the company achieved two key clinical milestones: the completion of full enrollment in its two phase 3 clinical trials of abicipar in wet AMD, and the dosing of the first patient in the phase 2 trial of MP0250 in multiple myeloma. In addition, the company diversified its shareholder base through the acquisition of a substantial portion of the venture capital investors’ shareholdings by new private investors.

Read More